Management Credibility Analysis
Upcoming Catalysts
Verified event feedCompany profile
No description available
- Chief executive
- Not disclosed
- Headquarters
- 63 SECOND AVENUE, BURLINGTON, MA
- Founded
- Not disclosed
📈 Company Timeline
LeMaitre Vascular, Inc. reported A director or senior management change or compensation event
LeMaitre Vascular, Inc. filed an 8-K covering a director or senior management change or compensation event.
LeMaitre Vascular, Inc. filed Form 10-Q
LeMaitre Vascular, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
LeMaitre Vascular, Inc. reported Operating or financial results
LeMaitre Vascular, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
Large-holder ownership filing
A holder reported or amended a beneficial ownership position of more than 5% in LeMaitre Vascular, Inc..
LeMaitre Vascular, Inc. reported Shareholder voting results
LeMaitre Vascular, Inc. filed an 8-K covering shareholder voting results.
Capital Structure & Financial Position
Financial strength and liquidity analysisSource: SEC EDGAR company facts (opens in a new tab) Balance sheet dated
Peer Comparison - Health Care
| Company | Price | Market Cap |
|---|---|---|
| LLY - Eli Lilly and Company |
$1,276.13
Yahoo Finance |
$1.20T |
| JNJ - Johnson & Johnson |
$256.74
Yahoo Finance |
$618.71B |
| ABBV - AbbVie Inc. |
$284.80
Yahoo Finance |
$503.28B |
| UNH - UnitedHealth Group Incorporated |
$418.43
Yahoo Finance |
$375.58B |
| MRK - Merck & Co., Inc. |
$148.55
Yahoo Finance |
$366.50B |
📋 Corporate Actions
Recent and upcoming corporate eventsFinancials
Financial statements and key metrics analysis| Quarter | Revenue (USD) | Operating income | Net income | Diluted EPS (USD) | Filed |
|---|---|---|---|---|---|
| Q4 2024 | $55.72M | $12.85M | $11.15M | Unavailable | 10-K · 28 Feb 2025 |
| Q3 2024 | $54.82M | $13.15M | $11.14M | $0.49 | 10-Q · 8 Nov 2024 |
| Q2 2024 | $55.85M | $14.38M | $11.83M | $0.52 | 10-Q · 8 Aug 2024 |
| Q1 2024 | $53.48M | $11.87M | $9.89M | $0.44 | 10-Q · 10 May 2024 |
| Q4 2023 | $48.88M | $10.21M | $8.47M | $0.38 | 10-K · 29 Feb 2024 |
| Q3 2023 | $47.41M | $9.18M | $7.50M | $0.33 | 10-Q · 8 Nov 2024 |
Analyst Consensus
Source: Nasdaq analyst research (opens in a new tab) Retrieved Targets range 81.00–120.00 Ratings are third-party opinions, not advice.
💰 Upcoming Dividends
Next dividend paymentsGuidance Evolution
💼 Director Transactions
Recent insider activityTop Shareholders
Source: Nasdaq institutional holdings (opens in a new tab) Observed · 11 hours ago